Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 1
1961 1
1962 2
1967 1
1973 1
1975 1
1976 3
1977 5
1978 4
1979 1
1980 1
1981 4
1982 4
1983 12
1984 13
1985 10
1986 5
1987 8
1988 17
1989 14
1990 16
1991 13
1992 14
1993 19
1994 25
1995 14
1996 18
1997 24
1998 14
1999 25
2000 20
2001 17
2002 12
2003 12
2004 13
2005 18
2006 24
2007 8
2008 28
2009 22
2010 18
2011 22
2012 19
2013 17
2014 36
2015 41
2016 41
2017 35
2018 30
2019 47
2020 32
2021 34
2022 47
2023 51
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

882 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for hairy, long
Search for hairu, long instead (2 results)
Hairy cell leukemia: present and future directions.
Kreitman RJ. Kreitman RJ. Leuk Lymphoma. 2019 Dec;60(12):2869-2879. doi: 10.1080/10428194.2019.1608536. Epub 2019 May 9. Leuk Lymphoma. 2019. PMID: 31068044 Free PMC article. Review.
Hairy cell leukemia (HCL) is an indolent B-cell malignancy, with long-term responses to purine analogs, but with decreasing efficacy and increasing toxicity with repeated courses. ...
Hairy cell leukemia (HCL) is an indolent B-cell malignancy, with long-term responses to purine analogs, but with decreasing ef …
Hairy-Skin-Adaptive Viscoelastic Dry Electrodes for Long-Term Electrophysiological Monitoring.
Tian Q, Zhao H, Wang X, Jiang Y, Zhu M, Yelemulati H, Xie R, Li Q, Su R, Cao Z, Jiang N, Huang J, Li G, Chen S, Chen X, Liu Z. Tian Q, et al. Adv Mater. 2023 Jul;35(30):e2211236. doi: 10.1002/adma.202211236. Epub 2023 Jun 9. Adv Mater. 2023. PMID: 37072159
Long-term epidermal electrophysiological (EP) monitoring is crucial for disease diagnosis and human-machine synergy. ...Therefore, accurate and high-quality EP signal detection remains challenging. To address this issue, a new solution-the hairy-skin-adaptive viscoe …
Long-term epidermal electrophysiological (EP) monitoring is crucial for disease diagnosis and human-machine synergy. ...Therefore, ac …
Long-term follow-up after purine analogue therapy in hairy cell leukaemia.
Else M, Dearden CE, Catovsky D. Else M, et al. Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29. doi: 10.1016/j.beha.2015.09.004. Epub 2015 Oct 9. Best Pract Res Clin Haematol. 2015. PMID: 26614900 Free PMC article. Review.
Since 2006 when we last reviewed the literature concerning the use of purine analogues in hairy cell leukaemia (HCL), results from several new and updated series have been published. ...Although they have not been compared in randomised trials, they appear to be equally ef …
Since 2006 when we last reviewed the literature concerning the use of purine analogues in hairy cell leukaemia (HCL), results from se …
Hairy Leukoplakia.
Rathee M, Jain P. Rathee M, et al. 2023 Apr 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Apr 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32119478 Free Books & Documents.
Hairy leukoplakia (HL) was first described in 1984 and is a disease of the mucosa. ...Such immunocompetent patients have shown to be on inhaled, topical, or systemic corticosteroids for the long term, which occur as a risk factor for developing the condition. ...
Hairy leukoplakia (HL) was first described in 1984 and is a disease of the mucosa. ...Such immunocompetent patients have shown to be …
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L, Criscuolo M, Broccoli A, Piciocchi A, Varettoni M, Galli E, Anastasia A, Cantonetti M, Trentin L, Kovalchuk S, Orsucci L, Frustaci A, Spolzino A, Volpetti S, Annibali O, Storti S, Stelitano C, Marchesi F, Offidani M, Casadei B, Nizzoli ME, De Luca ML, Fianchi L, Motta M, Guarnera L, Simonetti E, Visentin A, Vassallo F, Deodato M, Sarlo C, Olivieri A, Falini B, Pulsoni A, Tiacci E, Zinzani PL. Pagano L, et al. Blood Cancer J. 2022 Jul 19;12(7):109. doi: 10.1038/s41408-022-00702-9. Blood Cancer J. 2022. PMID: 35853850 Free PMC article.
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment with cladribine (2CDA), although relapse may occur during follow-up. The aim of the study is to review the efficacy, safety, long-term remission rate, and ove …
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment with cladribine (2CDA), a …
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Grever MR, et al. Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30. Blood. 2017. PMID: 27903528 Free PMC article.
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. ...Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particular …
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. ...De …
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ. Chihara D, et al. J Clin Oncol. 2020 May 10;38(14):1527-1538. doi: 10.1200/JCO.19.02250. Epub 2020 Feb 28. J Clin Oncol. 2020. PMID: 32109194 Free PMC article. Clinical Trial.
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituxim …
PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 …
Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
Hermel DJ, Cheng B, Bhangoo MS, Burian C, Waalen J, Saven A. Hermel DJ, et al. Ann Hematol. 2022 May;101(5):1089-1096. doi: 10.1007/s00277-022-04800-3. Epub 2022 Feb 26. Ann Hematol. 2022. PMID: 35218397
Hairy cell leukemia (HCL) is a rare hematologic disorder characterized by pancytopenia and splenomegaly for which a single course of cladribine is highly effective in inducing complete remissions. ...
Hairy cell leukemia (HCL) is a rare hematologic disorder characterized by pancytopenia and splenomegaly for which a single course of …
Long-term follow-up of patients with hairy cell leukemia in the south of Iran.
Dehghani M, Kashkooe A, Namdari N, Majidi R, Karimi M, Haghighat S, Rezvani A, Safari N. Dehghani M, et al. Expert Rev Hematol. 2023 Apr;16(4):289-295. doi: 10.1080/17474086.2023.2174520. Epub 2023 Feb 12. Expert Rev Hematol. 2023. PMID: 36709461
BACKGROUND: Hairy cell leukemia (HCL) is an indolent chronic lymphoproliferative disorder and first-line treatment with either intravenous or subcutaneous cladribine generally leads to long-lasting remissions. METHOD: All 131 patients with hairy-cell leukemia …
BACKGROUND: Hairy cell leukemia (HCL) is an indolent chronic lymphoproliferative disorder and first-line treatment with either intrav …
Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy.
Juliusson G, Samuelsson H; Swedish Lymphoma Registry. Juliusson G, et al. Leuk Lymphoma. 2011 Jun;52 Suppl 2:46-9. doi: 10.3109/10428194.2011.565842. Leuk Lymphoma. 2011. PMID: 21599605 Review.
Hairy cell leukemia is often reported as a disease of young males. ...Subcutaneous injection once daily is simple and effective due to 100% bioavailability and no local side effects from injection, and self-administration is easy. Long-term follow-up of Scandinavian …
Hairy cell leukemia is often reported as a disease of young males. ...Subcutaneous injection once daily is simple and effective due t …
882 results